Antagonism of Activin by Follistatin

Stable Identifier
R-HSA-2473224
Type
Pathway
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser

Both Follistatin (FST) and Follistatin-like-3 (FSTL3) irreversibly bind Activin dimers and prevent Activin from interacting with its receptor (reviewed in Schneyer et al. 2004, Xia and Schneyer 2009). Though functionally similar in vitro, FST and FSTL3 do not function identically in vivo. Mice lacking FST die shortly after birth due to defects in muscle and bone (Matzuk et al. 1995); mice lacking FSTL3 are viable but have altered glucose metabolism (Mukherjee et al. 2007).

Literature References
PubMed ID Title Journal Year
7885475 Multiple defects and perinatal death in mice deficient in follistatin

Matzuk, MM, Lu, N, Vogel, H, Sellheyer, K, Roop, DR, Bradley, A

Nature 1995
17229845 FSTL3 deletion reveals roles for TGF-beta family ligands in glucose and fat homeostasis in adults

Mukherjee, A, Sidis, Y, Mahan, A, Raher, MJ, Xia, Y, Rosen, ED, Bloch, KD, Thomas, MK, Schneyer, AL

Proc. Natl. Acad. Sci. U.S.A. 2007
19273500 The biology of activin: recent advances in structure, regulation and function

Xia, Y, Schneyer, AL

J. Endocrinol. 2009
15451564 Differential actions of follistatin and follistatin-like 3

Schneyer, A, Sidis, Y, Xia, Y, Saito, S, del Re, E, Lin, HY, Keutmann, H

Mol. Cell. Endocrinol. 2004
Participants
Participant Of
Orthologous Events
Authored
Reviewed
Created
Cite Us!